These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 9393874

  • 1. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
    Hernández-Alcoceba R, Saniger L, Campos J, Núñez MC, Khaless F, Gallo MA, Espinosa A, Lacal JC.
    Oncogene; 1997 Nov 06; 15(19):2289-301. PubMed ID: 9393874
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.
    Rodríguez-González A, Ramírez de Molina A, Fernández F, Ramos MA, del Carmen Núñez M, Campos J, Lacal JC.
    Oncogene; 2003 Dec 04; 22(55):8803-12. PubMed ID: 14654777
    [Abstract] [Full Text] [Related]

  • 4. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
    Hernández-Alcoceba R, Fernández F, Lacal JC.
    Cancer Res; 1999 Jul 01; 59(13):3112-8. PubMed ID: 10397253
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action.
    Rodríguez-González A, Ramirez de Molina A, Fernández F, Lacal JC.
    Oncogene; 2004 Oct 28; 23(50):8247-59. PubMed ID: 15378008
    [Abstract] [Full Text] [Related]

  • 7. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
    Ramírez de Molina A, Báñez-Coronel M, Gutiérrez R, Rodríguez-González A, Olmeda D, Megías D, Lacal JC.
    Cancer Res; 2004 Sep 15; 64(18):6732-9. PubMed ID: 15374991
    [Abstract] [Full Text] [Related]

  • 8. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors.
    Cuadrado A, Carnero A, Dolfi F, Jiménez B, Lacal JC.
    Oncogene; 1993 Nov 15; 8(11):2959-68. PubMed ID: 8414498
    [Abstract] [Full Text] [Related]

  • 9. Increased synthesis of phosphocholine is required for UV-induced AP-1 activation.
    Dong Z, Huang C, Ma WY, Malewicz B, Baumann WJ, Kiss Z.
    Oncogene; 1998 Oct 08; 17(14):1845-53. PubMed ID: 9778051
    [Abstract] [Full Text] [Related]

  • 10. Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells.
    Carnero A, Cuadrado A, del Peso L, Lacal JC.
    Oncogene; 1994 May 08; 9(5):1387-95. PubMed ID: 8152799
    [Abstract] [Full Text] [Related]

  • 11. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
    Ramírez de Molina A, Rodríguez-González A, Lacal JC.
    Cancer Lett; 2004 Apr 08; 206(2):137-48. PubMed ID: 15013519
    [Abstract] [Full Text] [Related]

  • 12. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.
    Lucas L, Hernández-Alcoceba R, Penalva V, Lacal JC.
    Oncogene; 2001 Mar 01; 20(9):1110-7. PubMed ID: 11314048
    [Abstract] [Full Text] [Related]

  • 13. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
    He H, Hirokawa Y, Levitzki A, Maruta H.
    Cancer J; 2000 Mar 01; 6(4):243-8. PubMed ID: 11038144
    [Abstract] [Full Text] [Related]

  • 14. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?
    Campos J, Núñez MC, Conejo-García A, Sánchez-Martín RM, Hernández-Alcoceba R, Rodríguez-González A, Lacal JC, Gallo MA, Espinosa A.
    Curr Med Chem; 2003 Jul 01; 10(13):1095-112. PubMed ID: 12678804
    [Abstract] [Full Text] [Related]

  • 15. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.
    Ramírez de Molina A, Gutiérrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sánchez JJ, Lacal JC.
    Oncogene; 2002 Jun 20; 21(27):4317-22. PubMed ID: 12082619
    [Abstract] [Full Text] [Related]

  • 16. New non-symmetrical choline kinase inhibitors.
    Schiaffino-Ortega S, López-Cara LC, Ríos-Marco P, Carrasco-Jimenez MP, Gallo MA, Espinosa A, Marco C, Entrena A.
    Bioorg Med Chem; 2013 Nov 15; 21(22):7146-54. PubMed ID: 24080101
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism.
    Rodríguez-González A, Ramírez de Molina A, Bañez-Coronel M, Megias D, Lacal JC.
    Int J Oncol; 2005 Apr 15; 26(4):999-1008. PubMed ID: 15753995
    [Abstract] [Full Text] [Related]

  • 18. Method of identifying inhibitors of oncogenic transformation: selective inhibition of cell growth in serum-free medium.
    Li PM, Fukazawa H, Yamamoto C, Mizuno S, Tanaka K, Hori M, Yaginuma S, Saito T, Uehara Y.
    Oncogene; 1993 Jul 15; 8(7):1731-5. PubMed ID: 8510919
    [Abstract] [Full Text] [Related]

  • 19. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
    Al-Saffar NM, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL.
    Cancer Res; 2006 Jan 01; 66(1):427-34. PubMed ID: 16397258
    [Abstract] [Full Text] [Related]

  • 20. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar 01; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.